Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flutiform versus formoterol in COPD exacerbation prevention
2012-004162-17Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Mundipharma. Primary endpoints: Annual rate of moderate and severe COPD exacerbations for flutiform 250/10 microg versus formoterol and Annual rate of moderate and severe COPD exacerbations for flutiform 125/5 microg versus formoterol. Started Apr 2013; status: completed.
02
Drugs
fluticasone propionateformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-004162-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004162-17.